Skip to main content

Luminex Corporation (LMNX)

Jul 14, 2021 - LMNX was delisted (reason: acquired by DiaSorin)
36.99 0.01 (0.03%)
Jul 13, 2021 4:00 PM EDT - Market closed
Market Cap1.75B
Revenue (ttm)437.66M
Net Income (ttm)23.13M
Shares Out45.89M
EPS (ttm)0.50
PE Ratio73.83
Forward PEn/a
Dividend$0.38 (1.03%)
Ex-Dividend DateJun 16, 2021
Volume-
Open-
Previous Close36.98
Day's Range36.98 - 37.00
52-Week Range20.41 - 41.14
Beta0.57
AnalystsHold
Price Target37.00 (+0.0%)
Est. Earnings DateAug 3, 2021

About LMNX

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a sof...

IndustryLife Sciences Tools & Services
IPO DateMar 30, 2000
Employees1,325
Stock ExchangeNASDAQ
Ticker SymbolLMNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Luminex stock is "Hold." The 12-month stock price forecast is 37.00, which is an increase of 0.03% from the latest price.

Price Target
$37.00
(0.03% upside)
Analyst Consensus: Hold

News

Luminex Corporation Declares Second Quarter Cash Dividend

AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10...

4 months ago - PRNewsWire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Luminex Corp. - LMNX

NEW YORK, April 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...

5 months ago - PRNewsWire

LUMINEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of P...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Luminex Corporatio...

6 months ago - Business Wire

Strength Seen in Luminex (LMNX): Can Its 12.4% Jump Turn into More Strength?

Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

6 months ago - Zacks Investment Research

INVESTIGATION ALERT: Halper Sadeh LLP Investigates LMNX, NUAN, CADE, GNMK; Shareholders are Encouraged to Contact the...

NEW YORK, April 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX)  concerning potent...

Other symbols:CADEGNMKNUAN
6 months ago - PRNewsWire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Luminex Corporation

NEW YORK, April 12, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Luminex Corporation (NASDAQ: LMNX) and its board of directors concerning the proposed acq...

6 months ago - PRNewsWire

Italian Diagnostic Developer Calls Luminex a 'Perfect Fit'

Investors reacted favorably over the announcement that Saluggia, Italy-based DiaSorin SpA (MIL:DIA) is paying $1.8 billion to purchase Austin, Texas-based Luminex Corp. (NASDAQ:LMNX), a developer of pro...

Other symbols:GNMKQDEL
6 months ago - GuruFocus

SHAREHOLDER ALERT: WeissLaw LLP Investigates Luminex Corporation

NEW YORK, April 12, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Luminex Corporation ("Luminex" or the ...

6 months ago - PRNewsWire

Shareholder Alert: Ademi LLP investigates whether Luminex Corporation has obtained a Fair Price in its transaction wi...

MILWAUKEE, April 12, 2021 /PRNewswire/ -- Ademi LLP is investigating Luminex (NASDAQ: LMNX) for possible breaches of fiduciary duty and other violations of law in its transaction with DiaSorin. Click he...

6 months ago - PRNewsWire

DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion

SALUGGIA, Italy, April 11, 2021 /PRNewswire/ -- DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement ...

6 months ago - PRNewsWire

Luminex Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Luminex Corporation I...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Luminex Corporation (NASDAQ: LMNX) to DiaSorin S.p.A. for $37.00 per share is fair to...

6 months ago - Business Wire

Here's Why You Should Retain Luminex (LMNX) Stock for Now

Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.

6 months ago - Zacks Investment Research

Luminex (LMNX) Files EUA Application for New Respiratory Assay

Luminex (LMNX) develops the combined assay to rapidly deliver clear solutions about respiratory infections from a single test.

7 months ago - Zacks Investment Research

Luminex (LMNX) Up 14.4% Since Last Earnings Report: Can It Continue?

Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

Luminex Submits Joint SARS-CoV-2 and Flu/RSV Respiratory Panel to FDA for Emergency Use Authorization

AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration...

7 months ago - PRNewsWire

Luminex Corporation to Participate at the 2021 Barclays Global Healthcare Conference

AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, Chairman, CEO & President, and Harriss Currie, Senior Vice President and CFO, plan to pa...

7 months ago - PRNewsWire

Luminex (LMNX) Surges 6.3%: Is This an Indication of Further Gains?

Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

7 months ago - Zacks Investment Research

Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG® Respiratory Panel Test Including SAR...

AUSTIN, Texas, March 4, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) fo...

7 months ago - PRNewsWire

Here's Why You Should Retain Luminex (LMNX) Stock for Now

Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.

7 months ago - Zacks Investment Research

Luminex Secures BARDA Funding To Develop And Validate Flu/COVID-19 Combo Respiratory Panel

Luminex Corporation (NASDAQ: LMNX) has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). It will support the rapid development and validation of ...

7 months ago - Benzinga

Luminex Receives BARDA Funding to Support Development and Validation of Test Combining SARS-CoV-2 and Flu/RSV Respira...

AUSTIN, Texas, Feb. 19, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $11.3 million in funding from the Biomedical Advanced Research and Development Author...

7 months ago - PRNewsWire

Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat

Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.

8 months ago - Zacks Investment Research

Luminex (LMNX) Q4 Earnings Miss Estimates

Luminex (LMNX) delivered earnings and revenue surprises of -92.86% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Recap: Luminex Q4 Earnings

Shares of Luminex (NASDAQ:LMNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 85.71% over the past year to $0.01, which missed the estimat...

8 months ago - Benzinga

Luminex Corporation Reports Fourth Quarter and Full-Year 2020 Results

AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release are in co...

8 months ago - PRNewsWire